Amplyx Pharmaceuticals is a pharmaceutical company focusing on the development of small molecule drugs, broad-spectrum antifungal agents for the treatment of life-threatening invasive fungal infections due to candida, aspergillus and rare molds. Existing therapies for invasive fungal infections are extremely limited on many fronts—they’re difficult to administer, can have toxic side effects and are ineffective against more potent fungi which have developed resistance. Amplyx is advancing a novel small-molecule therapy, APX001, in clinical development.
Latest funding size
Time since last funding
|7 months ago|
|Sofinnova Ventures, Pappas Capital, Arix Bioscience, New Enterprise Associates, RiverVest, Lundbeckfonden Ventures, BioMed Ventures, 3x5 Special Opportunity Fund|